BB
IONS icon

BB Biotech’s Ionis Pharmaceuticals IONS Stock Holding History

BB Biotech’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$627M Sell
7,725,000
-1,016,334
-12% -$65.6M 15.76% 1
2018
Q4 		$473M Buy
8,741,334
+75,000
+0.9% +$3.83M 15.14% 1
2018
Q3 		$447M Hold
8,666,334
– – 11.83% 1
2018
Q2 		$361M Buy
8,666,334
+150,000
+2% +$6.65M 10.43% 1
2018
Q1 		$375M Buy
8,516,334
+380,000
+5% +$19.3M 10.37% 1
2017
Q4 		$409M Buy
8,136,334
+274,400
+3% +$15M 11.52% 1
2017
Q3 		$399M Buy
7,861,934
+507,839
+7% +$26.6M 11.03% 3
2017
Q2 		$374M Sell
7,354,095
-107,200
-1% -$4.99M 11.43% 3
2017
Q1 		$300M Buy
7,461,295
+548,123
+8% +$24.6M 9.81% 3
2016
Q4 		$331M Sell
6,913,172
-250,000
-3% -$9.89M 12.25% 3
2016
Q3 		$262M Buy
7,163,172
+58,334
+0.8% +$1.83M 9.23% 3
2016
Q2 		$165M Buy
7,104,838
+325,000
+5% +$10.5M 6.53% 4
2016
Q1 		$275M Buy
6,779,838
+250,000
+4% +$10.2M 10.91% 3
2015
Q4 		$404M Sell
6,529,838
-105,000
-2% -$5.67M 11.39% 3
2015
Q3 		$268M Buy
6,634,838
+705,412
+12% +$36.5M 8.5% 5
2015
Q2 		$341M Buy
5,929,426
+200,000
+3% +$12.7M 9.25% 3
2015
Q1 		$365M Sell
5,729,426
-247,100
-4% -$16.8M 10.87% 2
2014
Q4 		$369M Sell
5,976,526
-660,000
-10% -$32.6M 11.95% 2
2014
Q3 		$258M Sell
6,636,526
-70,000
-1% -$2.48M 10.48% 3
2014
Q2 		$231M Buy
6,706,526
+405,000
+6% +$12.8M 10.98% 4
2014
Q1 		$272M Sell
6,301,526
-116,022
-2% -$5.62M 14.04% 2
2013
Q4 		$256M Sell
6,417,548
-785,037
-11% -$28M 13.66% 3
2013
Q3 		$270M Sell
7,202,585
-566,587
-7% -$16.9M 14.71% 2
2013
Q2 		$209M Buy
+7,769,172
New +$165M 15.04% 2

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BB Biotech's IONS Position: Q1 2019 in Review

BB Biotech reduced its Ionis Pharmaceuticals (IONS) stake by 12% in Q1 2019, selling an estimated $65.6M and leaving 7,725,000 shares worth $627M. The position accounts for 15.76% of the portfolio, ranked #1.

BB Biotech first reported a position in IONS in Q2 2013 and has held it in 24 quarters since. 392 funds tracked by Wall St. Rank hold IONS as of Q1 2019.

  • BB Biotech held 7,725,000 shares of Ionis Pharmaceuticals worth $627M as of Q1 2019.
  • BB Biotech sold 1,016,334 Ionis Pharmaceuticals shares in Q1 2019, an estimated $65.6M.
  • Ionis Pharmaceuticals made up 15.76% of BB Biotech's portfolio in Q1 2019, its #1 holding.
  • BB Biotech first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • 392 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.